GlassScriptPhysician profile
Kimball Pratt
NPI 1588608293
$5,822.39
in general payments reported to CMS, 2019-2025
27 companies · $1,340 in 2025
The $1,340 reported for 2025 was more than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $504 · 2020: $287 · 2021: $436 · 2022: $660 · 2023: $1,267 · 2024: $1,328 · 2025: $1,340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,923 · Education: $11.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,922.78 |
| Education | $11.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,741.46 | 2021-2025 | Percept PC Brainsense, Intellis Adaptivestim, Mazor X System |
| Abbott Laboratories | $637.62 | 2019-2025 | Eterna, Proclaim |
| Medtronic USA, INC. | $295.20 | 2019-2020 | |
| Si-Bone, INC. | $139.89 | 2020-2025 | |
| Boston Scientific Corporation | $116.33 | 2025 | General - Pain Management, Wavewriter Alpha Prime 16 |
| Alphatec Spine, INC | $108.54 | 2025 | Other - Miscellaneous |
| Ucb, INC. | $96.38 | 2025 | Zilbrysq, Rystiggo |
| Providence Medical Technology, INC. | $85.46 | 2025 | |
| Abbvie INC. | $80.42 | 2025 | |
| Sk Life Science, INC. | $57.06 | 2025 | |
| Argenx US, INC. | $45.97 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Lilly USA, LLC | $39.96 | 2024 | Emgality, Reyvow, Amyvid |
| Genzyme Corporation | $35.89 | 2025 | |
| Siemens Medical Solutions USA, INC. | $35.48 | 2022 | |
| Integra Lifesciences Corporation | $33.93 | 2025 | Duraseal Exact Spinal Sealant System, Codman Certas, Cusa Clarity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $30.22 | 2022 | |
| Genentech USA, INC. | $29.06 | 2024 | Ocrevus |
| Biogen, INC. | $28.50 | 2025 | Leqembi |
| Pacira Pharmaceuticals Incorporated | $26.83 | 2024 | Exparel, Zilretta, Iovera |
| Teva Pharmaceuticals USA, INC. | $26.43 | 2022 | |
| Neuropace, INC. | $25.18 | 2022 | |
| Nuvasive, INC. | $20.30 | 2019 | |
| Averitas Pharma INC. | $20.15 | 2025 | Qutenza |
| Stryker Corporation | $18.12 | 2022 | |
| Kyowa Kirin, INC. | $17.82 | 2024 | Nourianz |
| Amgen INC. | $16.24 | 2025 | Uplizna |
| Lundbeck LLC | $13.95 | 2023 | Vyepti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimball Pratt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.